Welcome to our dedicated page for Cosciens Biopharma news (Ticker: CSCI), a resource for investors and traders seeking the latest updates and insights on Cosciens Biopharma stock.
COSCIENS Biopharma Inc. develops and commercializes life science products spanning natural, plant-based active ingredients, pharmaceutical therapies and diagnostic products. Its portfolio includes Avenanthramides and Beta Glucan ingredients made with proprietary manufacturing and extraction technologies, as well as Macrilen® (macimorelin), an FDA- and EMA-approved oral diagnostic test for adult growth hormone deficiency.
Company news includes commercialization agreements for Macrilen, product registration and distribution activity, operating and financial results, cost-structure initiatives, board and leadership changes, shareholder matters and capital-structure updates. Coverage also reflects the company’s public-market status, including its continued TSX listing following Nasdaq delisting.
COSCIENS Biopharma Inc. (NASDAQ: CSCI) reported its Q2 2024 financial results, highlighting a net loss of $1.4 million ($0.64 per share) compared to $0.9 million ($0.47 per share) in Q2 2023. The company ended the quarter with $27.8 million in cash. Total revenue increased to $2.3 million from $1.4 million in the same period last year, driven by higher sales of Avenanthramides, Oat Beta Glucan, and Oat Oil.
Operating expenses rose to $4.5 million from $1.9 million, primarily due to increased R&D costs and administrative expenses related to the recent Aeterna-Ceapro acquisition. The company expects to announce top-line data from its DETECT-trial evaluating macimorelin for childhood-onset growth hormone deficiency diagnosis in Q3 2024.